sign in sign up
<<
Home , Comedocarcinoma, Gliosarcoma, Linitis plastica, Pancreatoblastoma

Example Registry Reportable List

This list provides example documentation of all conditions a cancer registry may consider reportable depending on the organizations the registry reports its data to. The reportable list for each cancer registry may vary. - It is structured alphabetically by the main histologic term. - Qualifiers and/or adjectives associated with the main term are included only if needed to specify when the condition is reportable. - An asterisk (*) to the right of a term denotes conditions not reportable when arising from skin except at a mucoepidermoid site as defined under Exclusions below. - The abbreviation “NOS” means “Not Otherwise Specified.”

Determining Reportable Conditions Using Histologic Terms - Conditions are to be reported if the diagnosis includes the terms cancer, , malignant, and lymphoma. - Most leukemias and are reportable except as noted as exclusions on the listing. - Other reportable conditions not containing these terms (i.e., refractory anemia, stromal endometriosis, Ewing tumor, carcinofibroma) also are included in this listing.

Determining Reportable Conditions Using ICD-O Behavior Codes - All cases with a behavior code of /2 (in situ) or /3 (malignant) in the International Classification of Diseases for Oncology (ICD-O), are reportable . - In addition, juvenile or pilocytic with a behavior code of /1 (uncertain/borderline) in ICD-O, Third Edition also is reportable using a behavior code of /3. - Note: If a pathologist verifies an ICD-O behavior code of /0 (benign) or /1 (uncertain) as “in situ” or “malignant,” these cases are reportable.

Exclusions Conditions are not to be reported if the diagnosis includes: Cervical intraepithelial neoplasia (CIN). Prostatic intraepithelial neoplasia (PIN). Squamous and basal cell primary to the skin: • Neoplasms, malignant, NOS of the skin (C44.0-C44.9) • Epithelial of the skin (C44.0-C44.9) • Squamous cell carcinomas of the skin (C44.0-C44.9) • Basal cell carcinomas of the skin (C44.0-C44.9) Note: The above lesions are reportable for squamous and basal cell cancers originating in mucoepidermoid sites: lip, anus, vulva, vagina, penis or scrotum (ICD-O codes C00.0-C00.9, C21.0, C51.0-C51.9, C52.9, C60.0-60.9, and C63.2).

Changes to December 2000 List of Abbreviated Reportable Conditions: • Reportable conditions from both the International Classification of Diseases for Oncology, Second Edition (ICD-O-2) and the Third Edition (ICD-O-3) are included in the listing. • Newly reportable conditions and terms with behavior changed from /1 (borderline) in ICD-O-2 to /3 (malignant) in ICD-O-3 are identified in bold print. These conditions are reportable only when diagnosed on or after January 1, 2001. • Several terms changed behavior from /3 (malignant) in ICD-O-2 to /1 (borderline) in ICD-O-3. These conditions are reportable only when diagnosed prior to January 1, 2001, and are identified in [brackets and italics]. • New terms and synonyms for existing ICD-O codes were added. Abstracting Methods Page 1 of 5 © 2005 AHIMA/NCRA

Adamantinoma (long bones, malignant, tibial only) papillary, borderline papillary mucinous, borderline malignancy Adenocarcinofibroma papillary pseudomucinous, borderline malignancy papillary serous, borderline Adenofibroma (malignant endometrioid only) malignancy pseudomucinous, borderline ( bronchial and malignancy serous, borderline malignancyonly)] cylindroid bronchial only) Cystosarcoma phyllodes (malignant only) Adenosarcoma Cytopenia, refractory with multilineage dysplasia AIN III (anal intraepithelial neoplasia, grade III) Dermatofibrosarcoma Ameloblastoma (malignant only) Diktyoma (exclude benign) Androblastoma (malignant only) DIN III (ductal intraepithelial neoplasia, grade III) Anemia, refractory Disease (include only: Angioendotheliomatosis alpha heavy chain Angiomyosarcoma Bowen* Angiosarcoma Di Guglielmo Argentaffinoma (malignant only) Franklin Arrhenoblastoma (malignant only) gamma heavy chain Heavy chain NOS Astrocytoma (exclude subependymal and Hodgkin desmoplastic infantile) immunoproliferative [NOS and small intestinal Astroglioma only] Blastoma* Letterer-Siwe Cancer* mast cell, systemic tissue Carcinoid (exclude tumor of appendix, strumal, Mu heavy chain argentaffin tumor NOS, Myeloproliferative, chronic, NOS enterochromaffin-like cell NOS, and tubular) Paget* [exclude of bone] Carcinofibroma Sezary) Carcinoma* Disorder, myeloproliferative, chronic Carcinomatosis* Disorder, primary cutaneous CD30+ T-cell lymphoproliferative CASTLE (Carcinoma showing thymus-like element) Dysgerminoma Chloroma Ectomesenchymoma Endometriosis, stromal Chondroblastoma (malignant only) Enteroglucagonoma (malignant only) Chondrosarcoma Ependymoblastoma Chordoma (exclude myxopapillary) Choriocarcinoma Epithelioma* (NOS, basal cell, malignant, and squamous Chorioepithelioma cell only) Chorionepithelioma Erythremia (acute and chronic only) Class IV cytology Erythroleukemia Class V cytology Erythroplasia, Queyrat* CPNET (central primitive neuroectodermal, NOS) Esthesioneurocytoma Cylindroma (exclude eccrine dermal, and skin) Esthesioneuroepithelioma (dermoid with malignant transformation only or Fibrochondrosarcoma dermoid with secondary tumor) Fibrodentinosarcoma Cystadenocarcinofibroma Fibroepithelioma, of Pinkus type or NOS* Fibroliposarcoma Cystadenofibroma (malignant endometrioid only) Fibromyxosarcoma [ (diagnosis date prior to January 1, 2001); Fibro-odontosarcoma (mucinous, borderline malignancy Abstracting Methods Page 2 of 5 © 2005 AHIMA/NCRA

Fibroxanthoma (malignant only) (anaplastic) Medullomyoblastoma Melanoma (exclude juvenile) (malignant only) Melanomatosis, meningeal Gemistocytoma Melanosis (precancerous only) Germinoma (malignant, anaplastic, papillary, or GIST-Gastrointestinal stromal tumor (malignant only) rhabdoid only) Mesenchymoma (malignant only) (exclude nasal and subependymal) Mesonephroma (exclude benign) (exclude benign and cystic) Gliosarcoma Metaplasia, agnogenic myeloid Glomangiosarcoma Microglioma (malignant only) MPNST, NOS (malignant peripheral nerve sheath Granuloma (Hodgkin only) tumor) Hemangioendothelioma (malignant only) Mycosis fungoides (malignant only) Myelofibrosis (acute, chronic idiopathic, with myeloid Hemangiosarcoma metaplasia or as a result of myeloproliferative disease only) Hepatocarcinoma Myeloma Hepatocholangiocarcinoma Myelomatosis Hepatoma (exclude benign) Myelosclerosis (megakaryocytic, acute, malignant or with Hidradenocarcinoma myeloid metaplasia) Hidradenoma (malignant only) Myelosis (malignant fibrous only) Myoblastoma (malignant granular cell only) Histiocytosis (malignant, and acute progressive X only) Myoepithelioma (malignant only) Histiocytosis, Langerhans cell, disseminated or generalized Myosis, stromal NOS or endolymphatic stromal Hutchinson melanotic freckle (melanoma In situ only) Myxoliposarcoma Hypernephroma Immunocytoma Neoplasia, ductal intraepithelial, grade 3 (of breast, (malignant only) also called DIN III) LCIS, NOS ( in situ) Neoplasia, intratubular germ cell Neoplasia, lobular, grade 2 of breast only (also called Lentigo maligna LN2) Leukemia (exclude granular lymphocytic) Neoplasia, squamous intraepithelial, grade 3 (of anus, vulva and vagina only - also called, (exclude well differentiated liposarcoma, AIN III, VIN III and VAIN III) superficial) , malignant* LN2 (of breast also called lobular neoplasia, grade 2 only) Nephroblastoma Lymphangioendothelioma (malignant only) Nephroma (exclude mesoblastic) Lymphangiosarcoma Neurilemmoma (malignant only) Lymphoblastoma Neurilemmosarcoma * Lymphoma , olfactory Lymphosarcoma Neuroepithelioma Macroglobulinemia, Waldenstrom Neurofibrosarcoma Malignancy* Neurosarcoma Malignant* Nevus (malignant blue only) (malignant only) Odontosarcoma Mastocytosis (malignant only) , mixed Oligodendroblastoma Abstracting Methods Page 3 of 5 © 2005 AHIMA/NCRA

Oligodendroglioma Struma (malignant ovarii and Wuchernde Orchioblastoma Langhans only) Osteochondrosarcoma Sympathicoblastoma Osteoclastoma (malignant only) Syndrome, Osteofibrosarcoma 5q deletion with myelodysplastic Osteosarcoma syndrome Hypereosinophilic Panmyelosis, acute only Myelodysplastic NOS , (anaplastic and with 5q deletion syndrome malignant only) therapy-related, NOS Papulosis, lymphomatoid therapy-related, alkylating agent (malignant only) related Paragranuloma, Hodgkin therapy-related, epidopophyllotoxin related Perineural MPNST Preleukemic Perineurioma (malignant only) Sezary Pheochromoblastoma Synovioma (NOS and malignant only) Pheochromocytoma (malignant only) chondroid, (malignant only) Pilomatrixoma* (malignant only) Teratoblastoma, malignant Pineoblastoma Teratocarcinoma Plasmacytoma Teratoma (embryonal, immature, malignant, and with PNET (primitive neuroectodermal tumor) malignant transformation only) Pneumoblastoma Thecoma (malignant only) Polycythemia (proliferative, rubra vera, or vera) Thrombocythemia (essential, essential hemorrhagic, Polyembryoma idiopathic, or idiopathic hemorrhagic) Polyposis (malignant lymphomatous only) (malignant or type C only) Porocarcinoma Tumor (include only: Poroma, eccrine (malignant only) adenocarcinoid PPNET (peripheral primitive neuroectodermal tumor) adrenal cortical (malignant only) Preleukemia alpha cell (malignant only) Askin Queyrat erythroplasia* Bednar Reticuloendotheliosis beta cell (malignant only) Reticulosarcoma Brenner (malignant only) Reticulosis (histiocytic medullary, malignant, pagetoid, Burkitt and polymorphic only) carcinoid, NOS (except of appendix) carcinoid (malignant only) desmoplastic small round cell Rhabdosarcoma embolus* (exclude well differentiated liposarcoma, endodermal sinus superficial) epithelial* (malignant only) Sarcomatosis (meningeal only) Ewing (malignant only) fibrous, solitary (malignant only) Seminoma follicular dendritic cell SETTLE (spindle epithelial tumor with thymus-like fusiform cell type* (malignant only) element) G cell (malignant only) (malignant only) gastrin cell (malignant only) Spermatocytoma gastrointestinal stromal (malignant only) Spiradenoma (malignant only) germ cell Spongioblastoma (polar or malignant only) giant cell (malignant only) Spongioneuroblastoma glomus (malignant only) Stromatosis, endometrial granular cell (malignant only) Abstracting Methods Page 4 of 5 © 2005 AHIMA/NCRA

granulosa cell (malignant or Sertoli-Leydig cell (poorly differentiated, with sarcomatoid only) Heterologous elements, sarcomatoid Grawitz (malignant only) interstitial cell (malignant only) sinus, endodermal intravascular bronchial alveolar small cell type* (malignant only) Klatskin (malignant only) Krukenberg spindle cell type* (malignant only) Leydig cell (malignant only) spindle epithelial with thymus-like element or thymus- malignant* (any type) like differentiation mast cell (malignant only) steroid cell (malignant only) Merkel cell sweat (malignant only) mesenchymal (malignant only) teratoid/rhabdoid, atypical mesodermal, mixed transitional pineal metastatic* triton, malignant mixed pineal trophoblastic, epithelioid mixed salivary gland type (malignant only) vitelline, polyvesicular [mucinous, of low malignant potential; Wilm diagnosis date prior to January 1, 2001] yolk sac mucocarcinoid Ulcer, rodent* Mullerian mixed VAIN III (vaginal intraepithelial neoplasia, grade 3) neuroectodermal (exclude melanotic) VIN III (vulvar intraepithelial neoplasia, grade 3) nonencapsulating sclerosing Vipoma (malignant only) odontogenic (malignant only) Xanthoastrocytoma, pleomorphic olfactory, neurogenic Pancoast [papillary mucinous, of low malignant potential; diagnosis date prior to January 1, 2001] [papillary serous, of low malignant potential; diagnosis date prior to January 1, 2001] peripheral neuroectodermal or peripheral primitive neuroectodermal, NOS peripheral nerve sheath (malignant only) phyllodes (malignant only) pineal parenchymal of intermediate differentiation Pinkus* plasma cell polyvesicular vitelline Tumor (include only count: primitive neuroectodermal rhabdoid, NOS rhabdoid/teratoid, atypical round cell, desmoplastic, small Schminke secondary* [serous, NOS, of low malignant potential serous, papillary, of low malignant potential; diagnosis date prior to January 1, 2001] Abstracting Methods Page 5 of 5 © 2005 AHIMA/NCRA